Table 2.
Selected clinical trials of immunotherapy by targeting CT antigens*
| Targeted CT antigen | Sponsor | Tumor histotype | Phase | Status | Identifier |
| NY-ESO-1 vaccine | ImmunoFrontier, Inc. | Solid tumors (e.g., melanoma, breast cancer, ovarian cancer, sarcoma and other expressing NY-ESO-1) | I | Ongoing 05/2011–12/2012 | NCT01234012 |
| NY-ESO Phase I Study for Prostate Cancer | Baylor College of Medicine | Prostate Cancer | I | Ongoing 06/2006–12/2016 | NCT00711334 |
| Infusion of genetically Engineered NY-ESO-1 T cells | University of Pennsylvania | synovial sarcoma | I | Ongoing 03/2011–03/2028 | NCT01343043 |
| MAGE-A3 Protein + AS15 for multiple myeloma patients undergoing autologous stem cell transplant | Ludwig Institute for Cancer Research/GlaxoSmithKline | Multiple Myeloma | I | Ongoing 06/2011–04/2014 | NCT01380145 |
| MAGE-A3 and NY-ESO-1 immunotherap in combination with DTPACE chemotherapy | Myeloma Institute for Research & Therapy, University of Arkansas | Multiple myeloma | I | Ongoing | NCT00090493 |
| MAGE-A3/recombinant protein immunotherapeutic vaccine | GlaxoSmithKline | Metastatic cutaneous melanoma | I | Completed, no study results posted | NCT00706238 |
| Melanoma Vaccine | Maria Sklodowska-Curie Memorial Cancer Center | Melanoma vaccine in patients with Stage III disease after lymph nodes removed | I & II | Completed, no study results posted | NCT01082198 |
| MAGRIT MAGE-A3 antigen Specific cancer immuno-therapeutic (ASCI)/MAGE-A3 Vaccine | GlaxoSmithKline | MAGE-A3 positive non small cell lung cancer (n = 2,270 patients) | III | Ongoing 10/2007–09/2022 | NCT00480025 |
| Four doses of MAGE vaccine using MAGE-A3 HPV-16 | University of Maryland and NIH | Squamous cell carcinoma of the head and neck | I | Completed, no study results posted | NCT00704041 |
| DERMA MAGE-A3 ASCI/MAGE-A3 recombinant Protein vaccine | GlaxoSmithKline | MAGE-A3 positive resected stage III melanoma (IIIB, IIIC, IIITx) (n = 1,300 patients) | III | Ongoing 12/2008–10/2016 | NCT00796445 |
| MAGE-A3/HPV16 vaccine | University of Maryland | Squamous cell carcinoma of the head and neck | I | Ongoing | NCT00257738 |
| Peptide vaccination using CA antigens from 3 peptides derived from URLC10, CDCA-1 and KOC1 | University of Yamanashi | Esophageal squamous cell carcinoma (local, advanced, recurrent or metastatic) (n = 60 patients) | II | Ongoing 04/2010–05/2012 | NCT01267578 |
*
HPV 16, human papillomavirus strain 16. Information was obtained from www.clinicaltrials.gov to compile this table. This table is not intended to be exhaustive, it provides some necessary information regarding the use of CT antigens for immunotherapy.